I-Mab Breaks Ground in Biopharmaceutical Industry Shanghai-based I-Mab, a clinical stage biopharmaceutical company, has been making waves in the field with its cutting-edge research in cancer and autoimmune disorder treatment. The company boasts an impressive product pipeline, including Felzartamab, a CD38 antibody currently in Phase 1b/2a for membranous nephropathy patients and Eftansomatropin alfa, a long-acting human growth hormone in Phase 3 clinical trials for pediatric growth hormone deficiency. Other offerings in its product catalog include Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trials, and Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, among others. I-Mab's strategic collaboration agreements with AbbVie Ireland Unlimited Company, Sinopharm Group Co. Ltd., PT Kalbe Genexine Biologics, and Roche Diagnostics have only increased its momentum in the industry. Founded in 2014, I-Mab has quickly established itself as a leading player in the biopharmaceutical space, and its innovative product pipeline and strategic partnerships show no signs of slowing down.